iQur is in the early stages of developing a preventative vaccine for hepatitis C in collaboration with researchers at the University of Nottingham.
Hepatitis C is thought to affect over 150 million people worldwide, leading to death from liver failure due to liver cirrhosis, or liver cancer in about a quarter of those infected. Although major advances in drug development have delivered drugs capable of curing hepatitis C in most patients, these drugs are costly and do not provide protection against reinfection. Hepatitis C is a global health problem and it is unlikely that costly drug treatments will be the means to achieve global control of the infection. Furthermore, no infectious disease has been eradicated without the use of a prophylactic (preventative) vaccine. iQur is deploying its vaccine development expertise to create a prophylactic vaccine against Hepatitis C.
Get in touch today to see how we could help you with your next project!